Form 4: Third Rock Ventures Sells 191,490 Shares of Tango Therapeutics

Third Rock Ventures IV, L.P. sold 191,490 shares of Tango Therapeutics (TNGX) common stock at a price of $9.8098 per share on July 18, 2024.

Summary

• On July 18, 2024, Third Rock Ventures IV, L.P. sold 191,490 shares of Tango Therapeutics, Inc. (TNGX) common stock.
• The sale price was $9.8098 per share.
• Following the transaction, Third Rock Ventures IV, L.P. directly holds 18,459,814 shares of Tango Therapeutics, Inc.
• The reporting entities include Third Rock Ventures IV, L.P., Third Rock Ventures GP IV, L.P., and TRV GP IV, LLC.
• Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, signed the Form 4 on behalf of all reporting entities.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of a share sale. The impact on the company depends on the reasons behind the sale and the market's perception.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or major shareholders of a publicly traded company buy or sell shares. This provides transparency to the market regarding the actions of those with privileged information.

Stakeholder Impact

• The sale of shares by a major shareholder like Third Rock Ventures could potentially influence investor sentiment and the stock price of Tango Therapeutics.

Key Dates